You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of liver homing PAR2 pepducins for the treatment of HepatocellularCarcinoma

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NCI

    Hepatocellular carcinoma (HCC) has become the second leading cause of cancer-related death in the world, with a 72% mortality rate in the US. The rise in incidence of HCC is due to a steady increase in the major risk factors of liver fibrosis, cirrhosis, and hepatitis B/C, with limited efficacy conferred by existing treatments at advanced stages of the disease. Systemic therapy with tyrosine kinas ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Smartphone App to Increase and Maintain Physical Activity in African American Men (FitBrothers)

    SBC: KLEIN BUENDEL, INC.            Topic: 102

    Physical activity (PA) is a modifiable risk factor for a number of preventable chronic diseases, including cardiovascular disease, strokes, obesity, and diabetes. These conditions constitute health disparities for African American men. Behavioral interventions have proven to be effective in promoting increases in physical activity. While behavior change programs have been shown to assist participa ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Development of small molecule RPN13 inhibitors for Treatment of Glioblastoma

    SBC: Up Therapeutics LLC            Topic: NCI

    Abstract. Glioblastoma (GBM) is an aggressive and deadly brain cancer with a one year median survival due to the lack of effective targeted treatments. Our goal is to develop a small molecule inhibitor targeting RPN13 protein in the 19S proteasome complex as a new drug for GBM. RPN13 is a proteasome ubiquitin receptor that recognizes ubiquitin-conjugated proteins that are thus tagged for degradati ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent

    SBC: PACDNA LLC            Topic: NCI

    Project Summary/AbstractMutant forms of KRAS are a key driver in human tumors but remain partially refractory to therapeutic intervention. After over three decades of research, only a single inhibitor (sotorasib) targeting a single mutation (KRASG12C) have reached market. The difficulty for developing small molecule KRAS inhibitors has heightened the importance of alternative methods targeting the ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Continuous Photoacoustic Monitoring of Neonatal Stroke in Intensive Care Unit

    SBC: BRIMROSE TECHNOLOGY CORP            Topic: NIBIB

    PROJECT SUMMARY/ABSTRACT Neonatal encephalopathy can arise from fetal hypoxia-ischemia during labor, chronic uteroplacental inflammation, and large cerebral artery embolization primarily arising from dislodgement of a placental thrombus. Because of overlapping clinical presentation, differential diagnosis is often delayed until seizures develop and MRI can be safely performed, a time at which most ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Targeting cadherin-11 in pancreatic cancer

    SBC: Diviner Therapeutics LLC            Topic: 102

    Pancreatic cancer is soon to be the second leading cause of cancer-related death with an overall median survival of 8 - 11 months. For 70% of patients, systemic chemotherapy is the only option and this mainly relieves the symptoms and/or slightly extends survival, rather than cures the patients. One of the hallmarks of PDAC is extensive fibrosis that comprises up to 80% of the tumor. Cancer-associ ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Preclinical testing of a 3D printed external scaffold device to prevent vein graft failure after coronary bypass graft surgery

    SBC: BIOGRAFT, INC.            Topic: NHLBI

    Saphenous vein graft (SVG) failure following coronary artery bypass grafting (CABG) is a critical clinical problem, with recent studies revealing that as many as 25% of vein grafts develop stenosis within 12-18 months after surgery, and up to 50% of grafts occlude within 5-10 years. CABG surgery is the gold standard treatment for patients with severe multi-vessel disease, with over 370,000 procedu ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Shim System for Removing ICD Artifacts from Patient Cardiac MR Images

    SBC: MIRTECH INC.            Topic: NHLBI

    Project Abstract1.4 million people in the US (2021) have implanted cardioverter-defibrillators (ICDs) of which ~50% will require an MRI scan in their lifetime. All ICDs generate large artifacts in MRI such as signal-voids in cardiac MR (cMR) images, which frequently occur in important pathological (infarcted) regions. Reliable diagnosis of ventricular tachycardia, premature ventricular contraction ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency

    SBC: COURAGE THERAPEUTICS INC            Topic: 102

    The melanocortin peptide therapeutic setmelanotide, (ImcivreeTM), is highly effective in the treatment of the rare obesity syndromes, POMC and leptin receptor deficiency. However, the drug is ineffective for the most common syndromic obesity, melanocortin-4 receptor (MC4R) deficiency (MC4R haploinsufficiency), found at a prevalence greater than 1/1000 individuals. Further, the drug is ineffective ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Making Connections Thru Music: A Group Music Therapy-Based Intervention for Persons with Dementia

    SBC: HOPEFUL AGING LLC            Topic: NIA

    PROJECT SUMMARY/ABSTRACTHealthcare systems around the world, including within the United States, have long-established shortages of trained caregivers (WHO, 2016; Jones, Liu, Murfield, andamp; Moyle, 2020). The American Health Care Association (2019) states that “the health care system has experienced a shortage of trained caregivers for critical roles for some time.” This scarcity directly im ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government